Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Pharmacy benefit manager Express Scripts, part of Cigna's Evernorth subsidiary, will be adding Humira biosimilars to its formulary in 2023 as preferred products, which will be available to patients ...

On the heels of a similar announcement from Optum Rx, pharmacy benefit management giant Express Scripts said Monday that it will add three biosimilars to its formulary to compete with Humira. The PBM ...

Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the ...

Express Scripts, the pharmacy benefits management business of the Cigna Group's Evernorth, will add three additional biosimilars to its National Preferred Formulary that it said will compete with ...

Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate ...

The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...